-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED says China NMPA approves ATLED for FGFR2-altered intrahepatic cholangiocarcinoma

PUBT·08/28/2026 00:00:20
Listen to the news
HUTCHMED says China NMPA approves ATLED for FGFR2-altered intrahepatic cholangiocarcinoma
  • China’s NMPA granted conditional clearance for ATLED (fanregratinib) to treat FGFR2 fusion/rearrangement intrahepatic cholangiocarcinoma in previously treated adults.
  • Approval supported by a China pivotal Phase II/IIIb study showing 42.5% objective response rate in pretreated advanced patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608272000PRIMZONEFULLFEED9817283) on August 28, 2026, and is solely responsible for the information contained therein.